Drug profile · INN
talquetamab-tgvs
TALVEY
talquetamab-tgvs (TALVEY) is a g-protein coupled receptor family c group 5 member d binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — talquetamab-tgvs
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
talquetamab-tgvs (TALVEY) is a g-protein coupled receptor family c group 5 member d binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
G-protein coupled receptor family C group 5 member D binding agent
Primary target: G-protein coupled receptor family C group 5 member D
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is talquetamab-tgvs?
talquetamab-tgvs (TALVEY) is a g-protein coupled receptor family c group 5 member d binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for talquetamab-tgvs?
TALVEY is a marketed brand name for talquetamab-tgvs. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of talquetamab-tgvs?
talquetamab-tgvs has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.